Safety Issues. Emisphere shall provide to Novartis within 48 hours of first receipt, any information concerning the safety profile of any of the Programme Carriers which may indicate a risk to patients. This shall include any adverse event reports suspected to be related to the Programme Carrier used in connection with any other active substance. In such an instance, Emisphere shall endeavor to promptly obtain any additional supporting information reasonably requested by Novartis.
Appears in 4 contracts
Samples: Research Collaboration License Agreement (Emisphere Technologies Inc), Research Collaboration License Agreement (Emisphere Technologies Inc), Research Collaboration License Agreement (Emisphere Technologies Inc)
Safety Issues. Emisphere shall provide to Novartis within 48 hours of first receipt, any information concerning the safety profile of any of the Programme Development Plan Carriers which may indicate a risk to patients. This shall include any adverse event reports suspected to be related to the Programme Development Plan Carrier used in connection with any other active substance. In such an instance, Emisphere shall endeavor to promptly obtain any additional supporting information reasonably requested by Novartis.
Appears in 3 contracts
Samples: Research Collaboration Option and License Agreement (Emisphere Technologies Inc), Research Collaboration Option and License Agreement (Emisphere Technologies Inc), Research Collaboration Option and License Agreement (Emisphere Technologies Inc)
